Beating the clock in T-cell acute lymphoblastic leukemia

William L. Carroll, Iannis Aifantis, Elizabeth Raetz

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

CDK4/6 inhibition was synergistic with dexamethasone and everolimus but antagonistic with conventional chemotherapy in T-cell acute lymphoblastic leukemia (T-ALL) preclinical models. Cyclin-dependent kinase inhibition in combination with glucocorticoids and mTOR inhibition offers a unique therapeutic opportunity in T-ALL.

Original languageEnglish
Pages (from-to)873-875
Number of pages3
JournalClinical Cancer Research
Volume23
Issue number4
DOIs
StatePublished - 15 Feb 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Beating the clock in T-cell acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this